GenEditBio to Present New Pre-Clinical Data for its Genome Editing and Delivery Platforms at the 27th Annual Meeting of the American Society of Gene and Cell Therapy

 

[April 30, 2024] – GenEditBio Limited (“GenEditBio”), a biotechnology start-up company focusing on genome-editing therapeutic solutions through the discovery of novel Cas nuclease and the development of safe and efficient cargo delivery platforms, today announced that the Company will have three poster presentations of pre-clinical data across platforms at the upcoming 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) to take place in Baltimore, Maryland, USA, May 7-11, 2024.

 

“We are excited to showcase our pioneering work in the discovery of novel Cas nucleases with high discriminating power between mutant and normal genes, as well as the exceptional safety profile of our engineered protein delivery vehicle (ePDV) platform with virtually no off-targeting effects. In addition, we will present our dataset on high-throughput screening of lipid nanoparticles in non-human primates for hepatic and extraheptic delivery,” said Zongli ZHENG, PhD, Chairman and Co-Founder of GenEditBio. “By unveiling our findings at the prestigious ASGCT meeting, we aim to not only share our cutting-edge advancements in the pursuit of efficient genome editing and safe in vivo delivery, but also connect with other stakeholders, including industrial partners and investors, to accelerate our pipeline development,” said Tian ZHU, PhD, CEO and Co-Founder of GenEditBio.

 

Details of the Company’s presentations are as follows -

 

Poster Presentations

  1. Title: A Catalogue of Novel Type II CRISPR Nucleases with Diverse PAM Preferences
    Abstract/Poster Board #: 716
    Session: Gene Targeting and Gene Correction New Technologies (C6)
    Presenter: Bang WANG, PhD
    Date and Time: May 8, 2024, 12:00 pm – 7:00 pm EDT

 

  1. Title: Engineering Virus-Like Particles to Deliver CRISPR-Cas9 Ribonucleoprotein In Vivo with Saturated Efficacy and Minimal Off-Target Effects
    Abstract/Poster Board #: 744
    Session: Other Nonviral Delivery (E2)
    Presenter: Zihua JIANG, BSc
    Date and Time: May 8, 2024, 12:00 pm – 7:00 pm EDT

 

  1. Title: High-Throughput Screening Powers the Discovery of Tissue-Specific Lipid Nanoparticles In Vivo
    Abstract/Poster Board #: 745
    Session: Other Nonviral Delivery (E2)
    Presenter: Zhixiong ZHOU, PhD
    Date and Time: May 8, 2024, 12:00 pm – 7:00 pm EDT

 

About GenEditBio

Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed “DNA surgery”) with high safety profile, unmatched precision, and affordable access for genetic diseases that currently lack cures or effective treatments. The Company’s core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing LNPs (lipid nanoparticles) and ePDVs (engineered protein delivery vehicles). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston. GenEditBio is financially backed by top-tier life science investors, including Qiming Venture Partners, Fangyuan Capital, Center Ventures, Lumosa Therapeutics, Innovation and Technology Venture of the HKSAR Government, and HKSTP Venture Fund.

 

Contact

bd@geneditbio.com

넳 넲